^
Association details:
| Biomarker: | EGFR mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | tigozertinib (BLU-945) (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC Estudio de fase 1/2 de los mecanismos de resistencia a anti-EGFR en el CPNM
Excerpt:
...1.≥18 years of age at the time of signing the informed consent.2.Pathologically confirmed, definitively diagnosed, metastatic NSCLC harboring an activating EGFR mutation.3.Previously received at least 1 prior EGFR-targeted TKI. ...
Trial ID:
Source:
Title:
BLU-945 monotherapy and in combination with osimertinib (OSI) in previously treated patients with advanced EGFR-mutant (EGFRm) NSCLC in the phase 1/2 SYMPHONY study.
Published date:
05/25/2023
Excerpt:
In the phase 1 dose escalation, pts (aged ≥18 y; metastatic EGFRm NSCLC; ECOG PS 0–1; treated with ≥1 EGFR TKI) received BLU-945 mono starting at 25 mg Q. Pts progressing on OSI could receive BLU-945 with 80 mg OSI starting at 50% of the highest safe BLU-945 mono dose....BLU-945 mono and combo with OSI were generally well tolerated and showed robust on-target EGFR ctDNA reduction, with tumor shrinkage in genomically heterogeneous, heavily pretreated pts.
DOI:
10.1200/JCO.2023.41.16_suppl.9011
Trial ID:
